MED17

Across TCGA pan-cancer cohorts, MED17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MED17 data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MED17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED17 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where MED17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.659	1.000	.006	14	view →
LUAD	DFS	Quartile	All	1.000	0.462	.020	7	view →
LSCC	DFS	Median	All	0.815	0.611	.024	5	view →
PDAC	DFS	Tertile	All	0.553	0.222	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MED17–CCRCC (DFS)

Open the CCRCC breakdown →